Research programme: cannabinoid therapeutics - Cannabis Biosciences

Drug Profile

Research programme: cannabinoid therapeutics - Cannabis Biosciences

Alternative Names: Phytocannabinoids - Cannabis Biosciences/Plandai Biotechnology; Phytofare® cannabinoid complex; Phytofare® cannabis extracts

Latest Information Update: 28 Jan 2015

Price : $50

At a glance

  • Originator Cannabis Bioscience
  • Class Cannabinoids
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Cancer; Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 26 Jan 2015 Plandai is collaborating with the University of Republic and Foundation for the Development of Basic Sciences agree to co-develop cannabinoid therapeutics in for Alzheimer's Epilepsy and Parkinson's and Cancer
  • 29 Oct 2014 Early research in Cancer in USA (unspecified route)
  • 09 Dec 2013 Early research in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top